Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.63 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | SOX18 | P35713 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.43 |
| ▸ | FNTB | P49356 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14169761 | 0.92 | CYP1A2 (0.68) | CYP1A2FFAR1TSHRSLC13A5PDPK1 | |
| SCHEMBL4988266 | 0.87 | CYP1A2 (0.56) | CYP1A2FFAR1SLC13A5PDPK1CYP2D6 | |
| SCHEMBL2172375 | 0.82 | TSHR (0.70) | FFAR1TSHRCYP2D6HDAC1HDAC8 | |
| SCHEMBL5060436 | 0.82 | CYP1A2 (0.52) | CYP1A2 | |
| SCHEMBL4984455 | 0.81 | SMN1; SMN2 (0.50) | CYP1A2TSHRCYP2D6HDAC1HDAC8 | |
| SCHEMBL30403190 | 0.81 | CYP1A2 (0.80) | CYP1A2FFAR1SLC13A5PDPK1CYP2D6 | |
| SCHEMBL1217683 | 0.81 | CYP1A2 (0.80) | CYP1A2FFAR1SLC13A5PDPK1CYP2D6 | |
| Hydrochloric Acid SCHEMBL27401796 | 0.79 | CYP1A2 (0.77) | CYP1A2FFAR1SLC13A5PDPK1CYP2D6 | |
| SCHEMBL23881672 | 0.79 | CYP1A2 (0.55) | CYP1A2FFAR1SLC13A5PDPK1CYP2D6 | |
| SCHEMBL2318140 | 0.78 | CYP1A2 (1.00) | CYP1A2FFAR1SLC13A5PDPK1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146524-A1 | Selective inhibitors of neurotensin degrading enzymes | SOLVAY PHARMACEUTICALS B.V. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146524-A1 | Selective inhibitors of neurotensin degrading enzymes | COMT, NTSR1, CMA1 | CYP1A2 467/4885FFAR1 3075/4885TSHR 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.